| 0 (0%) | 01-14 09:37 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 24.73 | 1-year : | 28.89 |
| Resists | First : | 21.18 | Second : | 24.73 |
| Pivot price | 17.97 |
|||
| Supports | First : | 17.47 | Second : | 15.18 |
| MAs | MA(5) : | 20.01 |
MA(20) : | 17.44 |
| MA(100) : | 14.88 |
MA(250) : | 12.61 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 85.4 |
D(3) : | 85.7  |
| RSI | RSI(14): 67.7 |
|||
| 52-week | High : | 21.18 | Low : | 6.78 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TXG ] has closed below upper band by 11.8%. Bollinger Bands are 97.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 20.75 - 20.85 | 20.85 - 20.94 |
| Low: | 19.27 - 19.38 | 19.38 - 19.48 |
| Close: | 20.35 - 20.53 | 20.53 - 20.68 |
Tue, 13 Jan 2026
Weak Instrument Sales And No 2026 Outlook Could Be A Game Changer For 10x Genomics (TXG) - Yahoo Finance
Tue, 13 Jan 2026
Analysts Offer Insights on Healthcare Companies: Stryker (SYK) and 10x Genomics (TXG) - The Globe and Mail
Mon, 12 Jan 2026
Why 10x Genomics (TXG) Shares Are Falling Today - Finviz
Mon, 12 Jan 2026
TXG: Strong revenue, product innovation, and AI partnerships drive growth amid challenging capital markets - TradingView — Track All Markets
Mon, 12 Jan 2026
10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease - PR Newswire
Mon, 12 Jan 2026
Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 116 (M) |
| Shares Float | 114 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 108.8 (%) |
| Shares Short | 15,420 (K) |
| Shares Short P.Month | 15,500 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.19 |
| Profit Margin | -11.9 % |
| Operating Margin | -21.2 % |
| Return on Assets (ttm) | -8.5 % |
| Return on Equity (ttm) | -10.2 % |
| Qtrly Rev. Growth | -1.8 % |
| Gross Profit (p.s.) | 3.79 |
| Sales Per Share | 5.51 |
| EBITDA (p.s.) | -0.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 89 (M) |
| Levered Free Cash Flow | 112 (M) |
| PE Ratio | -32.58 |
| PEG Ratio | 0 |
| Price to Book value | 3.3 |
| Price to Sales | 3.72 |
| Price to Cash Flow | 26.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|